In adults with moderately to severely active ulcerative colitis (phase 2b, n=137), week-14 clinical remission was 36% with duvakitug 450 mg and 48% with 900 mg vs 20% with placebo; both doses met the Bayesian efficacy threshold. Adverse events were similar.
RCTn = 137
Reinisch et al. Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial